Paediatric anaesthetic - Primex Pharmaceuticals

Drug Profile

Paediatric anaesthetic - Primex Pharmaceuticals

Latest Information Update: 20 Jun 2016

Price : $50

At a glance

  • Originator Advicenne
  • Developer Advicenne; Primex Pharmaceuticals
  • Class Anaesthetics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Anaesthesia

Most Recent Events

  • 07 Jun 2016 Primex Pharmaceuticals acquires oral paediatric anaesthetic from Advicenne
  • 30 Jun 2015 Clinical trials in Anaesthesia in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top